A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

Clinical trial NCT07157033 · RECRUITING

Trial details

NCT number: NCT07157033
Sponsor: Xerient Pharma
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Locally Advanced Pancreatic Adenocarcinoma Locally Advanced Pancreas Cancer Locally Advanced Pancreatic Ductal Adenocarcinoma

Start date: 2026-01-01
Primary completion: 2029-07-31
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.